Immunofoco is a clinical-stage biotech company, devoted to bringing revolutionary immune cell therapies to patients with solid tumors worldwide. The company was established in September 2020 in Zhangjiang, Shanghai, by a team of renowned scientists and industry experts among whom possess successful experience in introducing the first CAR-T product to the Chinese market.

Immunofoco has pioneered a clinical strategy that“curing the solid tumors by treating them as hematologic malignancies”, drawing from the challenges faced in solid tumor treatment and the clinical advantages of treating hematologic malignancies. To improve the safety of CAR-T products, counteract tumor heterogeneity, and enhance their effectiveness in tumor amplification and infiltration, while achieving cost reduction and efficiency improvement, we have developed innovative platforms such as Peri Cruiser, SNR, T-Booster, FOCO-CAR, and In Vivo.

Driven by clinical outcomes, our company maintains an extensive spectrum of product pipelines. Notably, IMC002, a CLDN18.2-targeted CAR-T therapy, has progressed to a Phase III pivotal trial in China. This follows its IND approvals from both U.S. and Chinese authorities in April 2023, and it holds U.S. FDA Fast Track designation along with Orphan Drug Designations for both gastric and pancreatic cancer. Similarly, our IMC001 (EpCAM CAR-T) product obtained ODD from the U.S. FDA in August 2023, and its IND application has been approved in both the U.S. and China in February 2024, followed by the approval of a second IND in China in March 2025. The IMC008 (SNR CAR-T) product has rapidly moved to the IIT stage and received two ODD approvals from the U.S. FDA in August 2023.

In December 2022, we successfully completed the construction validation of our nearly 2500m2 GMP plant in Suzhou and commenced operations. Additionally, our commercial manufacturing base in Chengdu is currently under construction. The company upholds the development concept of “collaborative effort and aspirations, striving for new heights,” by assembling industry talents and expert support to jointly develop innovative cell therapies that provide long-term survival benefits to patients with solid tumors. For more information about Immunofoco, please visit the company’s website at www.immunofoco.com.